Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
National Institutes of Health
Inicia sesión y completa tu Funding Passport para ver si calificas — un veredicto transparente basado en reglas, no una caja negra.
Iniciar sesiónSobre esta oportunidad
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Documentos requeridos
La fuente oficial no indica documentos específicos aquí — confirme los requisitos antes de postular.
Fuente y trazabilidad de verificación
- Fuente oficial
- U.S. Federal Government (Grants.gov) ↗
- Primera obtención
- 20 de noviembre de 2026
- Última verificación
- 20 de noviembre de 2026
- Huella del contenido
527f382e82e39ff8…